Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Ariad Pharmaceuticals, Inc.    ARIA   US04033A1007

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/20/2015 02/23/2015 02/24/2015 02/25/2015 02/26/2015 Date
8.06(c) 7.81(c) 7.78(c) 8.04(c) 8.17(c) Last
23 419 748 10 036 738 6 677 556 7 068 978 8 037 461 Volume
+10.87% -3.10% -0.38% +3.34% +1.62% Change
More quotes
Company
ARIAD Pharmaceuticals, Inc. operates as a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer.The company has four products: Ridaforolimus, Ponatinib, AP1903 and AP26113.Its approach to structure-based drug... 
Sector
Pharmaceuticals
Calendar
02/25 | 08:00amPresentation
More about the company
Surperformance© ratings of Ariad Pharmaceuticals, Inc
Trading Rating : Investor Rating :
More Ratings
Chart ARIAD PHARMACEUTICALS, INC
Duration : Period :
Ariad Pharmaceuticals, Inc Technical Analysis Chart | ARIA | US04033A1007 | 4-Traders
Full-screen chart
Financials ($)
Sales 2015 151 M
EBIT 2015 -181 M
Net income 2015 -185 M
Finance 2015 80,5 M
Yield 2015 -
Sales 2016 212 M
EBIT 2016 -136 M
Net income 2016 -124 M
Finance 2016 76,8 M
Yield 2016 -
PER 2015 -
PER 2016
EV / Sales 2015 9,42x
EV / Sales 2016 6,73x
Capitalization 1 505 M
More Financials
Latest news on ARIAD PHARMACEUTICALS, INC
02/25 ARIAD PHARMACEUTICALS : Reports 2014 Financial Results, Provides 2015 Financial ..
02/24 ARIAD PHARMACEUTICALS : to Present at the Cowen and Company 35th Annual Health C..
02/23 ARIAD PHARMACEUTICALS : Where Investors Are Going: Special Research on Springlea..
02/20 ARIAD PHARMACEUTICALS : Confirms Receipt of Sarissa Capital Management’s N..
02/19 ARIAD PHARMACEUTICALS : to Present at the RBC Capital Markets' Healthcare Confer..
02/19 ARIAD PHARMACEUTICALS : reports 4Q loss
02/19 ARIAD PHARMACEUTICALS : Results of Operations and Financial Condition, Regulatio..
02/19 ARIAD PHARMACEUTICALS : Reports 2014 Financial Results, Provides 2015 Financial ..
More news
Sector news Biopharmaceuticals
07:06p GILEAD SCIENCES : Announces Phase 3 Results for Investigational Once-Daily Singl..
06:54p GILEAD SCIENCES : Bristol-Myers: Drug combo cured hepatitis C in 97% with HIV
06:40p NOVO NORDISK A/S : receives Health Canada approval for Saxenda® (liraglutide) fo..
Plus d'actualités du secteur Biopharmaceuticals


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF